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Abstract
Background: We explored the association of mammographic density, a breast cancer risk factor,
with hormonal and proliferation markers in benign tissue from tumor blocks of pre-and
postmenopausal breast cancer cases.
Methods:  Breast cancer cases were recruited from a case-control study on breast density.
Mammographic density was assessed on digitized prediagnostic mammograms using a computer-
assisted method. For 279 participants of the original study, we obtained tumor blocks and prepared
tissue microarrays (TMA), but benign tissue cores were only available for 159 women. The TMAs
were immunostained for estrogen receptor alpha (ERα) and beta (ERβ), progesterone receptor
(PR), HER2/neu, Ki-67, and Proliferating Cell Nuclear Antigen (PCNA). We applied general linear
models to compute breast density according to marker expression.
Results: A substantial proportion of the samples were in the low or no staining categories. None
of the results was statistically significant, but women with PR and ERβ staining had 3.4% and 2.4%
higher percent density. The respective values for Caucasians were 5.7% and 11.6% but less in
Japanese women (3.5% and -1.1%). Percent density was 3.4% higher in women with any Ki-67
staining and 2.2% in those with positive PCNA staining.
Conclusion:  This study detected little evidence for an association between mammographic
density and expression of steroid receptors and proliferation markers in breast tissue, but it
illustrated the problems of locating tumor blocks and benign breast tissue samples for
epidemiologic research. Given the suggestive findings, future studies examining estrogen effects in
tissue, cell proliferation, and density in the breast may be informative.
Background
Although a vast body of literature describes a positive
association between mammographic density and breast
cancer risk with an estimated relative risk of 4 or higher for
women in the highest as compared to the lowest density
category [1], not much is known about the underlying his-
topathology of breast density [2]. Such knowledge may
contribute to breast cancer prevention because it may
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improve our understanding of the relation between den-
sity and breast cancer risk as well as the potential for risk
prediction and modification. The two types of tissue that
give rise to radiologically dense breasts are epithelium and
stroma forming the microenvironment of epithelial cells
which constitute less than 5% of breast tissue [3,4]. The
main component of stromal tissue is collagen [5]. It was
hypothesized that the extent of mammographic density is
proportional to the amount of breast epithelium and that
the higher breast cancer risk associated with breast density
is due to a larger number of glandular cells at risk for
malignant transformation [6,7]. This idea is supported by
findings of an association between the proliferation of
stroma, epithelium, or both with breast density in subjects
with breast abnormalities [8,9]. Unfortunately, research
in healthy women is limited to forensic studies [10,11]
and one study of breast reduction samples [5]. In breast
cancer patients, increased amounts of collagen were asso-
ciated with breast density in several reports [5,9,11,12],
while the results on cell proliferation were mixed
[5,13,14].
As risk factors that induce cell proliferation [15,16],
endogenous sex steroids and hormone therapy (HT) are
associated with higher breast cancer risk [17,18]. Whereas
HT, in particular estrogen plus progestogen therapy,
increases mammographic density [19], the relation
between endogenous sex steroids and mammographic
density is less clear. One study observed an association
with endogenous estrogens [20] but others did not [21-
23]. As breast tissue levels are partly determined by estro-
gen production in adipose tissue, breast size as marker for
adipose tissue surrounding the epithelial cells may possi-
bly be a better marker for tissue levels than circulating
estrogen levels. Endogenous progesterone was found to
be related to mammographic density in one report among
premenopausal women [24]. The biological activities of
endogenous and exogenous estrogens on breast tissue are
mediated by nuclear estrogen receptors (ER) α and β. Dif-
ferential effects of ERα and ERβ are of interest because ERβ
appears to be more antiproliferative while ERα has prolif-
erative activity [25,26]. Progesterone, an ovarian steroidal
hormone, acts through its specific receptor (PR) [27,28];
PR expression has been shown to be a sensitive indicator
of estrogenic effects in cells [29].
To understand how hormone receptors and cell prolifera-
tion are related to breast density, this study examined the
expression of ERα, ERβ, and PR as well as HER2, Ki-67,
and Proliferating Cell Nuclear Antigen (PCNA) [30], in
relation to mammographic density among breast cancer
patients with Caucasian, Japanese, and Hawaiian ethnic-
ity. We are convinced that these associations are best stud-
ied in benign breast tissue and, thus, restricted this
analysis to breast cancer patients for whom benign tissue
samples placed on tissue microarrays (TMA) were availa-
ble. The relation between mammographic appearance of
the breast and marker expression in tumor tissue is a sep-
arate issue that needs further study [31].
Methods
Study population
The study was approved by the Institutional Review
Boards of the University of Hawaii and Wake Forest Uni-
versity; all subjects provided informed consent in writing.
We recruited subjects for the TMA study from 607 breast
cancer cases who had participated in the Multiethnic
Cohort (MEC) [32] and a nested case-control (NCC)
study of mammographic densities [33]. Of these, 177
women were excluded because their tumor blocks were
not available from the Hawaii Tumor Registry (HTR).
Recruitment letters and questionnaires were mailed to the
remaining 430 subjects; 323 (75%) women returned the
consent forms. Another 12 women were deceased but
linked to the HTR and could, thus, be included in the
study. For 279 out of these 335 subjects, pathologic blocks
from breast cancer surgery were located and used to create
TMAs; no tissue from prior benign biopsies was available.
At entry into the MEC, all participants had completed a
questionnaire that inquired about demographics, repro-
ductive behavior, anthropometric measures, and family
history of breast cancer [32]. As part of the NCC, women
completed an additional one-page breast health question-
naire that asked about previous breast surgery, menopau-
sal status, mammography history, and HT use [33].
Tumor microarrays
TMAs were prepared according to standard procedures
[34,35]. In brief, a surgical pathologist (JK) identified
blocks from a given patient with sufficient tissue. For each
of these blocks a single hematoxylin and eosin (H&E)
slide was prepared on which the same pathologist marked
representative areas of malignant and benign tissue. The
H&E slide was aligned with the corresponding "donor"
block and a 0.6 mm cylindrical tissue specimen was taken
from the selected area and transferred to a "recipient" par-
affin block using a tissue-arraying instrument (Beecher
Instruments, Sun Prairie, WI). When available, four malig-
nant cores and four benign cores per patient were placed
in one of six blocks. Out of the 2,232 cores to be placed
(four malignant and four benign samples for 279
women), tissue was insufficient for 12% of malignant and
29% of benign specimens resulting in 1,773 tissue sam-
ples (79.4%) for analysis. At least one benign or malig-
nant core was available for 268 women. Several 5 μm
sections were mailed to Wake Forest University for immu-
nohistochemical staining.
Immunohistochemistry and pathologic evaluation
The TMAs were stained for the following markers: ERα,
ERβ, PR, and PCNA (Clones 6F11, EMR02, 1A6, and
PC10, respectively; all from Novocastra Labs, Newcastle-BMC Cancer 2009, 9:182 http://www.biomedcentral.com/1471-2407/9/182
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upon-Tyne, UK), Ki-67 (Clone SP6, Labvision NeoMark-
ers, Fremont, CA), and HER2/neu 1 (rabbit polyclonal,
DAKO Corporation, Carpinteria, CA). The basic staining
procedure used an avidin-biotin-alkaline phosphatase
method, modified for antigen retrieval from paraffin-
embedded tissue using the procedure of Shi et al [36]. Fol-
lowing overnight incubation with the primary antibodies
at 4°C, tissue sections were sequentially incubated with a
biotinylated secondary antibody and a streptavidin-alka-
line phosphatase conjugate at 37°C for 20 minutes,
respectively, (Biogenex, San Ramon, CA, USA) and then
visualized using the chromogen/substrate Vector Red
(Vector Laboratories, Burlingame, CA, USA). Sections
were counterstained with Mayer's hematoxylin, dehy-
drated, cleared through p-Xylene, and coverslipped.
Appropriate positive and negative controls were included
for each antibody. During staining, about 7–9% of the
samples fell off the slides. The number was similar across
epithelial markers, but twice as many benign as malignant
samples were missing.
When a trained pathologist (JMC) evaluated all stained
specimens to confirm their malignancy status and the
presence of epithelial tissue, 118 breast tissue samples
were re-categorized as benign or malignant, i.e., the core
had been taken from a malignant part of the block
although the intent had been to get a benign sample or
vice versa. Another 409–433 (depending on the marker)
core sections with equivocal features, e.g., connective tis-
sue or fat tissue only or bad dye quality, were excluded. As
a result, at least one benign tissue sample was available for
159 women (mean = 1.7 specimens per woman). Quanti-
fication of staining was done on individual TMA core sec-
tions at a magnification of 20×, using a Nikon Labophot
2 microscope, a 3 megapixel digital camera (Infinity 2–3,
Lumenera Inc., Ottawa, Ontario), and color imaging soft-
ware (Image Pro Plus, Media Cybernetics, Bethesda, MD).
The area of all nuclei in the core section was measured by
a color selection corresponding to hematoxylin (A). The
area of positively immunostained tissue was measured by
a color selection corresponding to the Vector Red chro-
mogen (B). For the nuclear stains used in this study, the
percentage of staining was expressed as B/A × 100; results
were averaged for subjects with several cores.
Mammographic density assessment
Breast density readings used for the present study had all
been obtained previously as part of the NCC study [33].
All mammographic films were scanned with a Kodak
LS85 Film Digitizer (absorbance range, 0.001–4.1; East-
man Kodak Company, Rochester, New York) at a resolu-
tion of 98 pixels per inch. One of the authors (GM)
performed computer-assisted density assessment with the
Cumulus package [37]. After the reader determined a
threshold for the edge of the breast and the dense tissue,
the computer computed the number of pixels that consti-
tuted the total and the dense area and the ratio between
the two, i.e., percent breast density. To convert the pixels
of the area into cm2, a factor of 0.000676 was used. The
intraclass correlation coefficients (ICC) to assess reliabil-
ity were 0.96 (95% confidence interval (CI): 0.95, 0.97)
and 0.996 (95% CI: 0.995, 0.997) for the size of the dense
and the total breast area, respectively. This resulted in an
ICC of 0.974 for percent density (95% CI: 0.968, 0.978).
For the present study, the cranial caudal view closest to,
but before, breast cancer diagnosis was selected; the mean
time between the two dates was 10.0 ± 14.8 months.
Statistical analysis
SAS statistical software package version 9.1 was used for
all analyses (SAS Institute Inc., Cary, NC). The dense
breast area was square root transformed to normalize the
distribution. For ease of interpretation, back transformed
mean values are presented. For all histology markers, the
mean percentage of stained cells of all available cores per
sample was calculated. To assess marker agreement by
subject, ICCs were computed. For all six markers, the dis-
tributions of samples were skewed with strong left tails.
The interquartile ranges were 0.0–8.1%, 0.0–13.8%, 0.0–
1.5%, 0.0–14.5%, 0.0–0.6%, 0.8–16.2% for ERα, ERβ,
PR, HER2, Ki-67, and PCNA, respectively. Therefore, sam-
ples were divided into two categories; negative staining
(<10% of cells stained) and positive staining (≥ 10% of
cells). Because the number of women with positive stain-
ing for PR and Ki-67 was very low (4 and 13 respectively),
we dichotomized the results into no vs. any epithelial
staining. Linear regression models were used to analyze
the association between histological markers as categori-
cal variables and mammographic density (absolute den-
sity and percent density) as continuous variables.
Associations were adjusted for variables previously shown
to be associated with mammographic density including
age at mammogram, body mass index (BMI), ethnicity,
age at menarche, parity, age at first live birth, HT use at
mammogram, menopausal status, and family history of
breast cancer. Separate analyses stratified by ethnicity
(Caucasian and Japanese) and by total size of the breast
with the median as cutpoint were also performed.
Results
Women in the TMA study were slightly younger, were
more likely premenopausal, and had a lower BMI than in
the original NCC study, but were otherwise similar (Table
1). The study population included 49 Caucasians, 70 Jap-
anese, 21 Native Hawaiians, and 19 women of other eth-
nicities. Mean total breast area as measured on the
mammograms was largest for Caucasian women and
smallest for Japanese women (135 and 91 cm2, respec-
tively). BMI and total breast area were strongly correlated
0.52 (p < 0.0001). Absolute mammographic density wasBMC Cancer 2009, 9:182 http://www.biomedcentral.com/1471-2407/9/182
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highest in Caucasian women and in the subgroup of
women with other ethnicities (43 cm2) and lower in
Hawaiian (36 cm2) and Japanese women (34 cm2). Per-
cent mammographic density was highest among the sub-
group of women with other ethnicities (50%) and lowest
in Hawaiian women (30%), while it was intermediate in
Japanese (40%) and Caucasians (38%).
A substantial proportion of the samples were in the low or
no staining categories (Table 2). The percentages were
88%, 70%, 49%, 67%, 42%, and 60% for ERα, ERβ, PR,
HER2, PCNA, and Ki-67, respectively. A similar propor-
tion of Japanese and Caucasian women were in the high-
est staining category for all markers; none of the
differences was statistically significant. The sample size
was too small to examine other ethnic groups. Small dif-
ferences in breast density were seen between staining cat-
egories of several markers, but, with two exceptions in the
subgroup of Caucasians, none of the results were statisti-
cally significant. Percent density was higher in the overall
and stratified analyses for subjects with PR staining (all
women: 3.4%; Caucasian: 5.8%; Japanese: 3.5%). In
women with higher ERβ staining, percent density was
higher in the total population and in Caucasians (2.4%
and 11.6%) but not in Japanese. No associations of per-
cent density with ERα and HER2/neu were observed. Per-
cent density was somewhat higher in women with Ki-67
staining, both in the total population (3.4%) and in Cau-
casians (3.8%) and Japanese (4.4%). Positive PCNA stain-
ing showed slightly higher percent density in all women
and in Japanese but not in Caucasians.
As an exploratory analysis, we stratified by total breast
area to capture possible effects due to high adiposity.
More women with large breasts had PR expression than
women with small breasts (58% vs. 44%, p = 0.08) (Table
3). The opposite was seen for ER expression (ERα: 62% vs.
77%, p = 0.44; ERβ: 56% vs. 65%, p = 0.30). Women with
large breasts and positive staining for all markers, except
Ki-67, had higher percent densities, especially for PR
(6.2%), ERβ (6.4%), and PCNA (4%). Although not sta-
tistically significant, women with small breasts who
stained for hormonal markers showed slightly lower per-
cent density except for PR with 4.3% higher density in cat-
egory 2. Those with positive Ki-67 staining had 4.4%
higher density, whereas positive staining for PCNA made
no difference among women with small breasts. With few
exceptions, the associations with absolute area were simi-
lar to the findings with percent density. Restricting the
analyses to postmenopausal women did not change the
results; no significant associations were observed (data
not shown).
Discussion
This investigation of breast density and immunohisto-
chemical marker expression in TMAs observed no signifi-
cant associations in the entire study population, but it
appeared that mammographic density was slightly higher
for women with PR expression as compared to those with
no PR expression. This observation was consistent across
the two major ethnic groups and women with different
breast sizes. The difference between low and high catego-
ries was 3–4% in density which, if a true finding, may
translate into a 6–8% higher breast cancer risk [33]. Only
in women with large breasts, mammographic density was
slightly higher in subjects with ERα, ERβ, and HER2
expression, but again, the results were not statistically sig-
nificant. For category 2 expression of Ki-67 and PCNA,
percent breast density was slightly higher in the entire
population. The findings in Caucasians who, on average,
have larger breasts than Japanese largely reflected the
results in the subgroup of women with large breasts,
whereas the findings in Japanese women tended to be
closer to the results of women with small breasts. The
Table 1: Characteristics of women recruited for the TMA study 
and the original study*
Variable Original study TMA study
Sample size (N) 607 159
Ethnicity (%)
Caucasian 185 (30.5) 49 (30.8)
Hawaiian 80 (13.2) 21 (13.2)
Japanese 287 (47.3) 70 (44.0)
Other 55 (9.1) 19 (12.0)
Age at mammogram 62.1 ± 8.5 59.8 ± 8.7
Body mass index (m/kg2) 25.1 ± 5.1 24.4 ± 4.3
Family history of breast cancer (%) 104 (17.1) 17 (10.7)
Age at menarche (%)
< 13 years 324 (54.4) 86 (54.1)
13–14 years 217 (36.4) 58 (36.5)
>14 years 55 (9.2) 15 (9.4)
Number of children (%)
0–1 172 (28.3) 43 (27.0)
2 to 3 312 (51.4) 86 (54.1)
>3 123 (20.3) 30 (18.9)
Age at first live birth (%)
<21 years 80 (13.6) 21 (13.2)
21–30 years 359 (61.0) 102 (64.2)
>30 years 56 (9.5) 11 (6.9)
N/A 94 (16.0) 25 (15.7)
HT use at mammogram (%)
No use 264 (43.5) 64 (40.3)
Estrogen only 174 (28.7) 46 (28.9)
Estrogen plus progestogen 169 (27.8) 49 (30.8)
Breast measures
Total breast area 117.9 ± 58.1 110 ± 52.9
Breast density in percent 35.3 ± 23.3 38.4 ± 24.8
Absolute density 35.9 ± 27.0 39.5 ± 23.4
Menopausal Status (%)
Premenopausal 152 (25.0) 60 (37.7)
Postmenopausal 455 (75.0) 99 (62.3)
* Means ± standard deviation unless stated otherwiseBMC Cancer 2009, 9:182 http://www.biomedcentral.com/1471-2407/9/182
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higher percent density among women with Japanese
ancestry despite their lower breast cancer risk was also
observed in the original study [33]. It is due to the small
breast sizes that result in a higher percent of the breast
occupied by dense tissue. As shown in cross-sectional
comparisons, the size of the dense area appears to be a
better indicator of risk when different ethnic groups are
compared [38,39].
Six previous reports examined the underlying histological
markers for breast density; one study used forensic breast
samples [11], one examined reduction mammoplasty
samples [5], one collected fine needle biopsies [13], two
used tissues surrounding non-cancerous breast lesions
[9,12], and another one identified non-cancerous tissue
from mastectomy specimens [14]. Of these six studies,
only one study assessed ERα and PR expression and did
not find an association, but the sample size was only 56
[14]. Three studies looked at Ki-67 expression; one found
no association with mammographic density [13], one
found a positive association [14], and one described less
proliferation in dense areas [5]. As far as we know, no pre-
vious results for ERβ, HER2/neu, and PCNA have been
reported.
The observation that in women with small breasts, per-
cent density was slightly lower for those with higher ER
expression, whereas it was higher in women with large
breasts and positive ER expression suggests that a possible
effect of ER expression on breast density, if it exists, may
depend on the amount of local estrogens. Apart from
ovarian production, estrogens are metabolized from
androgens in adipose tissue [40]. Thus, in women with
large breasts, tissue estrogen levels would also be higher
due to the larger amount of fat tissue. This idea agrees with
a report that women with a nipple aspirate fluid (NAF)
phenotype characterized by higher BMI and percentage
body fat had higher NAF estrogen levels [41]. Therefore,
Table 2: Marker expression and mammographic density by ethnicity
Marker All women (n = 159) Caucasian (n = 49) Japanese (n = 70)
Category* Category Category
1 2 P-value 1 2 P-value 1 2 P-value
ERα % density† 36.9 35.6 0.75 39.8 23.9 0.04 38.8 44.5 0.39
Dense area# 33.7 33.6 0.98 38.2 26.2 0.18 33.8 38.0 0.50
N u m b e r 1 2 23 5 3 81 1 5 31 6
ERβ % density 35.8 38.2 0.49 33.8 45.4 0.05 40.2 39.1 0.85
Dense area 33.0 34.6 0.66 34.4 40.9 0.38 35.2 33.3 0.74
N u m b e r 1 1 04 7 3 61 3 4 72 1
PR % density 34.9 38.3 0.28 35.3 41.0 0.30 37.5 41.0 0.57
Dense area 30.6 36.4 0.09 31.1 45.9 0.03 35.2 34.4 0.90
Number 77 81 23 25 35 35
HER2/neu % density 37.1 36.3 0.82 35.7 40.9 0.38 41.3 37.9 0.57
Dense area 34.4 33.2 0.74 36.4 36.5 0.99 35.5 33.6 0.73
N u m b e r 1 0 45 2 3 41 5 4 52 3
Ki-67 % density 34.3 37.7 0.32 35.5 39.3 0.53 36.8 41.2 0.46
Dense area 32.9 33.5 0.87 38.7 34.9 0.60 32.8 35.3 0.66
Number 65 90 16 32 31 39
PCNA % density 36.0 38.2 0.50 37.7 37.1 0.91 38.7 42.2 0.52
Dense area 33.4 33.7 0.94 36.7 36.4 0.97 35.1 33.9 0.82
Number 95 63 28 20 42 28
* Categories for ERα, ERβ, HER2/neu and PCNA; category 1 <10% staining, category 2 ≥ 10% staining. Categories for PR and Ki-67; category 1 = 
no staining, category 2 = any staining
† Mean percent breast density
# Mean dense area in cm2
Mean values and p-values calculated using general linear models adjusted for age at mammogram, BMI, ethnicity, HT use at mammogram, 
menopausal status, parity, age at first live birth, age at menarche and family history of breast cancer.
(ERα = estrogen receptor alpha; ERβ = estrogen receptor beta; PR = progesterone receptor; HER2/neu = Human Epidermal growth factor 
receptor2; PCNA = Proliferating Cell Nuclear Antigen; BMI = body mass index)BMC Cancer 2009, 9:182 http://www.biomedcentral.com/1471-2407/9/182
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the higher PR expression in women with large breasts as
compared to women with small breasts may reflect
responsiveness to estrogen [29]. Despite the non-signifi-
cant results, these observations may indicate that higher
ER expression in combination with high tissue levels of
estrogens influence breast density.
This epidemiologic investigation took advantage of the
TMA approach that allows assessment of marker expres-
sion in a large number of pathologic samples under simi-
lar staining conditions [34,42]. Another benefit of TMAs
was that multiple markers could be analyzed using sec-
tions of the TMA block without exhausting the material.
However, a disadvantage of the method is the loss of sam-
ples during immunostaining due to lack of adhesion to
glass slides and cross-sectional variation in the amount of
epithelial tissue. The use of cores with a larger diameter
may alleviate that problem. Alternatively, immunohisto-
chemistry could be performed on full sections, if they are
available. Another issue with TMAs is that consecutive sec-
tions may reveal different types of tissue for the same core
due to heterogeneity with tissue depth. As shown before,
benign tissue samples were more affected than malignant
cores [42,43]. Since a maximum of 4 benign core sections
per woman was placed, information on a substantial
number of women was obtained. Despite identifying
benign specimens for only 159 out of 279 subjects due to
the difficulties with benign tissue in the tumor blocks, lit-
tle evidence for selection bias was detected (Table 1).
Obviously benign biopsies would be the preferred source
of material for this type of research because benign tissue
adjacent to tumor tissue may be different from benign tis-
sue in the other breast or in breast tissue of women with-
out cancer. Unfortunately, that type of tissue is not easy to
obtain. The amount of material available from stereotactic
biopsies is often too small for TMA preparation and
women with benign biopsies cannot be identified
through tumor registries. Although breast reduction sur-
gery would yield large amounts of tissue, women under-
going that procedure represent a selected subgroup with
Table 3: Marker expression and mammographic density stratified by total breast size
Marker Small total breast area Large total breast area
Category* Category
1 2 P-value 1 2 P-value
ERα % density† 41.3 38.0 0.55 30.7 33.7 0.61
Dense area# 29.5 29.1 0.92 34.6 39.7 0.53
Number 63 16 59 19
ERβ % density 41.3 39.5 0.71 29.9 36.3 0.24
Dense area 28.9 29.7 0.82 34.1 41.2 0.34
Number 50 29 60 18
PR % density 39.0 43.3 0.36 27.1 33.3 0.19
Dense area 28.8 29.8 0.78 28.3 40.0 0.05
Number 45 36 32 45
HER2/neu % density 41.7 39.8 0.71 30.4 33.5 0.51
Dense area 30.3 28.6 0.65 35.2 37.6 0.71
Number 55 24 49 28
Ki-67 % density 38.2 42.6 0.35 29.7 30.9 0.81
Dense area 25.4 31.8 0.07 35.8 34.5 0.85
Number 30 49 35 41
PCNA % density 41.0 39.9 0.81 29.9 33.9 0.43
Dense area 29.4 28.8 0.86 33.7 40.5 0.32
Number 43 38 52 25
* Categories for ERα, ERβ, HER2/neu and PCNA; category 1 <10% staining, category 2 ≥ 10% staining. Categories for PR and Ki-67; category 1 = 
no staining, category 2 = any staining
† Mean percent breast density
# Mean dense area in cm2
Mean values and p-values calculated using general linear models adjusted for age at mammogram, BMI, ethnicity, HT use at mammogram, 
menopausal status, parity, age at first live birth, age at menarche and family history of breast cancer.
(ERα = estrogen receptor alpha; ERβ = estrogen receptor beta; PR = progesterone receptor; HER2/neu = Human Epidermal growth factor 
receptor2; PCNA = Proliferating Cell Nuclear Antigen; BMI = body mass index)BMC Cancer 2009, 9:182 http://www.biomedcentral.com/1471-2407/9/182
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predominantly fatty breast tissue and different mammo-
graphic patterns [44].
Conclusion
This investigation illustrates the problems of obtaining
benign breast tissue samples for a representative sample of
participants in epidemiologic studies. To benefit from the
advantages of the TMA technique in future research, it is
recommended to select the areas for taking the tissue cores
carefully and to minimize the loss of specimens during
immunostaining. Based on our few suggestive findings,
future mammographic density investigations may pursue
estrogenic effects as assessed by PR and cell proliferation
using Ki67 and other such markers to examine the ques-
tion of local estrogen activity in relation to breast density.
The slightly higher breast density with PR expression sug-
gests a stronger estrogenic response in mammographically
dense breasts possibly leading to stronger cell prolifera-
tion, an idea supported by associations of breast density
with hyperplasia and other benign breast pathology
[8,10,45,46]. Although not statistically significant, the
higher breast density with steroid receptor expression in
women with large breasts as compared to women with
small breasts indicates a role of locally produced estrogens
in women with more adipose tissue [40]. On the other
hand, it is most likely that chance was responsible for the
small differences observed in this exploratory study.
Given the weak associations in the current investigations
and the discrepant findings across studies, the roles of
growth factors and the properties of the stromal matrix in
shaping breast density also deserve further attention
[4,9,12].
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